Your browser doesn't support javascript.
loading
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Int J Cancer ; 132(7): 1581-91, 2013 Apr 01.
Article in En | MEDLINE | ID: mdl-22948952

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Peptide Fragments / Polyethylene Glycols / Colorectal Neoplasms / Tumor Suppressor Protein p53 / Interferon-gamma / Interferon-alpha / Cancer Vaccines / Liver Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Cancer Year: 2013 Type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Peptide Fragments / Polyethylene Glycols / Colorectal Neoplasms / Tumor Suppressor Protein p53 / Interferon-gamma / Interferon-alpha / Cancer Vaccines / Liver Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Cancer Year: 2013 Type: Article Affiliation country: Netherlands